Avatrombopag achieved a durable platelet response in 28% of pediatric patients with persistent or chronic immune thrombocytopenia (ITP), compared to 0% with placebo.
81% of avatrombopag-treated patients showed at least two consecutive platelet responses versus none in the placebo group.
The safety profile was reassuring, with no deaths, thromboembolic events, or severe bleeding episodes.
Avatrombopag offers a convenient oral option with flexible administration and no dietary restrictions for children and adolescents with ITP.
